Smartest Doc
Serum Hepatocyte Growth Factor and Interleukin-6 Are Effective Prognostic Markers for Non-small Cell Lung Cancer
Anticancer Research, 07/27/2012
Clinical Article
Ujiie H et al. – The levels of hepatocyte growth factor (HGF) and interleukin–6 (IL–6) in serum could be useful prognostic indicators of the survival of patients with stage III NSCLC undergoing surgery and chemotherapy.
Methods- The authors obtained preoperative serum from 109 patients, and measured the levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), and nicotinamide N-methytransferase (NNMT) in the sera.
- The median HGF and IL-6 contents were 860pg/ml and 2.7 pg/ml, respectively.
- Analysis of survival curves indicated that an HGF or IL-6 level higher than the median was associated with poor overall survival (HGF, p=0.019; IL-6, p=0.002).
- In addition, they analyzed stage III lung cancer alone.
- Higher HGF and IL-6 levels were associated with poor overall survival (HGF, p=0.016; IL-6, p=0.013).
- Disease-free survival was not statistically significantly affected by these cytokine contents.
- The tumor status (pT factor) and nodal status (pN factor) were not associated with the survival of stage III patients.
